Bristol-myers Squibb Compnay

Syngene International Limited

Susheel Jethanand Nara

Soodamani Thangavel

Srinivas Cheruku

John E Macor

Joanne J Bronson

Carolyn Diane Dzierba

James Aaron Balog

Ramesh Kumar Sistla

Ramkumar Rajamani

Saumya Roy

Weifang Shan

Steven P Seitz

David K Williams

Jay A Markwalder

Maheswaran Sivasamban Karatholuvhu

Dean A Wacker

Audris Huang

Vivekananda M Vrudhula

Kandhasamy Sarkunam

Srinivasan Thangathirupathy

Prasada Rao Jalagam

Firoz Ali Jaipuri

Srinivas Jogi

Emily Charlotte Cherney

Tarun Kumar Maishal

Senliang Pan

Rishikesh Narayan

Nagalakshmi Pulicharla

Pavan Kalyan Kathi

Natesan Murugesan

Pratik Devasthale

Richard A Hartz

Manoranjan Panda

Weiwei Guo

Jonathan L Ditta

Yadagiri Kanyaboina

Alicia Regueiro-Ren

Guanglin Luo

Ling Chen

Bireshwar Dasgupta

Vijay T Ahuja

Subba Reddy Bandreddy

Chunjian Liu

Wei Meng

Bruce A Ellsworth

Satheesh Kesavan Nair

Guohua Zhao

Yanting Huang

Liping Zhang

Elizabeth Anne Jurica

Jianxin Feng

David S Yoon

Rushith Kumar Anumula

Ximao Wu

Kamalraj Thiyagarajan

Rajamani Ramkumar

Murugesan Natesan

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, when Q is: (i) halo, cyano, hydroxyl, NRR, C(O)OH, C(O)NH, Calkyl substituted with zero to 6 R, or P(O)RR, or (ii) L R; and A, X, X, X, X, Z, Z, R, R, R, R, R, R, R, L, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Substituted amide compounds useful as farnesoid X receptor modulators

The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. (Formula (I))

Small molecule inhibitors of galectin-3

The present disclosure relates to compounds of Formula (I) or Formula (II), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

The present disclosure relates to compounds of Formula (I) or (II), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

Small molecule inhibitors of Galectin-3

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein Q is Calkenyl or Calkynyl, each substituted with zero to 2 R; and the other variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Substituted bicyclic compounds as farnesoid X receptor modulators

The present invention provides compounds of formula (I) wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.

Inhibitors of indoleamine 2,3-dioxygenase and methods of their use

The present invention provides compounds of formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.

Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is a 5-membered heterocyclyl or 5-membered heteroaryl having 1 to 4 heteroatoms independently selected from N, O, and S, substituted with zero to 4 R; and A, X, X, X, X, Z, Z, R, R, R, R, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the disclosure.

The present invention provides compounds of Formula (I): 

Bridged bicyclic compounds as farnesoid X receptor modulators

The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia. 

Biaryl kinase inhibitors

Growing community of inventors

Bengaluru, India

Susheel Jethanand Nara